Besides the challenges posed by the globally circulating COVID-19 pandemic, there have been some epochal advances in the field of vaccine technologies. In addition to traditionally used inactivated, live, and protein-based vaccines, vector- and gene-based vaccines have gained enormous attention in the course of this health crisis. The aim of this article is to provide an overview of multiple sclerosis (MS) and vaccination, recent advances in the SARS-CoV-2 vaccine landscape, and a detailed discussion of various vaccine technologies. Finally, clear recommendations within the framework of disease-modifying treatment and vaccination in MS will be highlighted.
